TRPV2 Agonists in the Fontan Circulation

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 21, 2017

Primary Completion Date

June 30, 2020

Study Completion Date

December 31, 2020

Conditions
Fontan
Interventions
DRUG

Probenecid

This is a cross-over pilot study where participants will receive both the study medication (probenecid), as well as a placebo to see if the study medication improves magnetic resonance parameters of systolic and diastolic dysfunction that occurs in the Fontan population.

OTHER

Placebo

placebo

Trial Locations (1)

45229

Cincinnati Childrens Hospital Medical Center, Cincinnati

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT03965351 - TRPV2 Agonists in the Fontan Circulation | Biotech Hunter | Biotech Hunter